Cempra’s solithromycin gets FDA fast track status to treat CABP
Currently, solithromycin is in Phase III development for the treatment of CABP and submission of a new drug application (NDA) is planned for 2016. The company is carrying
QIAGEN’s Digital Insights bioinformatics division is set to integrate NVIDIA’s accelerated computing and the BioNeMo platform to enhance AI-driven drug discovery.
Developed for the prescription market and formulated with the patented Microcyn Technology, the product is being made available via the company’s dermatology division IntraDerm Pharmaceuticals. Alevicyn SG Antipruritic